December 11th, 2017
jobs
homes

Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Neurogene Inc. - Common Stock (NQ:NGNE)

30.42 +3.43 (+12.71%)
Delayed Quote Updated: 4:00 PM EDT, Oct 28, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Neurogene Inc. - Common Stock

< Previous 1 2 Next >
Which stocks are moving on Friday? ↗
Via Chartmill
News headline image
Why Did NGNE Stock Surge 25% In Pre-Market Today? ↗
The company said that the U.S. Food and Drug Administration granted a key designation for its investigational gene therapy targeting Rett syndrome. 
Via Stocktwits
Wondering what's happening in today's after-hours session? ↗
Via Chartmill
News headline image
FDA's Rigid Approach Adds Uncertainty To uniQure's Accelerated Pathway For Huntington's Gene Therapy ↗
William Blair notes FDA's tougher stance on gene therapy programs as AMT-130 faces uncertainty in its accelerated approval timeline. 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Thursday's Intraday Session ↗
 
Via Benzinga
News headline image
4 Biotech Stocks Seeing Explosive Momentum Gains ↗
The SPDR S&P Biotech ETF (ARCA:XBI) is up more than 40% over the past six months and is on the verge of breaking out. Here's a look at several momentum standouts in the biotech space that appear to be... 
Via Benzinga
Topics ETFs Stocks
News headline image
FDA Outlines Process To Speed Up Rare Disease Therapy Approvals ↗
FDA launches Rare Disease Evidence Principles to guide therapy reviews, offering new pathways for approval while raising questions on development impact. 
Via Benzinga
News headline image
Vinay Prasad's Comeback To FDA Sparks Debate Over Regulatory Direction ↗
Vinay Prasad returns as FDA's CBER director after brief exit, raising questions on rare disease drug approvals and mRNA vaccine oversight. 
Via Benzinga
News headline image
What's Going On With Sarepta, Capricor And Other Gene Therapy Stocks On Wednesday? ↗
Vinay Prasad exits FDA's biologics division following pressure over Sarepta's Elevidys approval and regulatory controversies. 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Friday's After-Market Session ↗
 
Via Benzinga
News headline image
Which stocks are moving on Tuesday? ↗
Keep an eye on the top gainers and losers in Tuesday's session, as they reflect the most notable price movements. 
Via Chartmill
News headline image
12 Health Care Stocks Moving In Tuesday's Intraday Session ↗
 
Via Benzinga
News headline image
Which stocks are experiencing notable movement on Tuesday? ↗
Intrigued by the market activity in the middle of the day on Tuesday? Uncover the key winners and losers of today's session in our insightful analysis. 
Via Chartmill
News headline image
This Foot Locker Analyst Is No Longer Bullish; Here Are Top 3 Downgrades For Friday ↗
 
Via Benzinga
News headline image
Coinbase To Rally Around 17%? Here Are 10 Top Analyst Forecasts For Wednesday ↗
 
Via Benzinga
News headline image
Stanley Black & Decker To Rally Around 24%? Here Are 10 Top Analyst Forecasts For Tuesday ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Monday's Intraday Session ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
J.M. Smucker Posts Upbeat Earnings, Joins LexinFintech, Semtech, Arrowhead Pharmaceuticals And Other Big Stocks Moving Higher On Tuesday ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Monday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Crude Oil Rises Sharply; US Homebuilder Sentiment Surges In November ↗
 
Via Benzinga
News headline image
Neurogene, Nvidia And Other Big Stocks Moving Lower In Monday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Dow Falls 100 Points; Brady Posts Upbeat Results ↗
 
Via Benzinga
Topics Stocks
News headline image
Neurogene — Down 36% — Extends Losses After Side Effect Derails Its Rett Syndrome Drug ↗
The company is now scrapping a high dose of its Rett syndrome drug after a patient experienced a serious side effect. 
Via Investor's Business Daily
News headline image
Earnings Scheduled For November 15, 2024 ↗
 
Via Benzinga
News headline image
Neurogene Stock Plummets 44%: Is All Hope Lost for This Biotech?"
Neurogene has been on a huge run in 2024. That came to a halt after the company released trial results. But, the results may be better than the market thinks. 
Via MarketBeat
News headline image
12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Dow Dips Over 200 Points; Home Depot Posts Upbeat Earnings ↗
 
Via Benzinga
Topics Stocks
News headline image
Neurogene Stock Tanks After Adverse Event In Early-Stage Rett Syndrome Gene Therapy Trial ↗
Neurogene reports interim Phase 1/2 trial results for NGN-401 gene therapy in treating pediatric Rett syndrome, showing improved safety and efficacy. 
Via Benzinga
News headline image
Top 1% Biotech Neurogene Crashes, Wiping Out A Run, On A Serious Side Effect ↗
Neurogene tested its gene therapy in female patients with Rett syndrome. 
Via Investor's Business Daily
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

More ways to get to us

Lethbridge Herald Facebook Facebook
Lethbridge Herald Twitter Twitter
Lethbridge Herald YouTube YouTube

About Us

Contact the Lethbridge Herald

504 - 7th Street South
Lethbridge, AB T1J 3Z7

[P] (403) 328-4411
[F] (403)328-4536

Print Advertising: (403) 328-4410
National Advertising: (403) 380-7585
Online Advertising: (403) 380-7585
Classifieds: (403) 328-4433

© 1996-2017 The Lethbridge Herald, A Division of Continental Newspapers Canada Ltd.